1. Home
  2. BIIB

BIIB

Biogen Inc.

Logo Biogen Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 2:30pm EST

$
-
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Founded: 1978 Country:
United States
United States
Employees: 7570 City: CAMBRIDGE
Market Cap: 28.1B IPO Year: 1991
Target Price: $296.20 AVG Volume (30 days): 1.2M
Analyst Decision: Buy Number of Analysts: 25
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 7.97 EPS Growth: -61.81
52 Week Low/High: $197.79 - $319.76 Next Earning Date: 04-24-2024
Revenue: $9,835,600,000 Revenue Growth: -3.32%
Revenue Growth (this year): -1.95% Revenue Growth (next year): 1.36%

Share on Social Networks: